Table 4 |
|||||
|
Model-adjusted mean saliva and urinary biomarker levels pre- and post-law, Ontario, 2005-06 |
|||||
|
Biomarker |
Pre (95% CI) |
Post (95% CI) |
Change |
B |
p |
|
|
|||||
|
Breath CO (ppm)1 |
4.6 (3.7, 5.4) |
4.8 (3.9, 5.7) |
4.3% |
0.26 |
0.580 |
|
Saliva Cotinine2 (ng/mL) |
303.9 (242.0, 381.7) |
351.1 (291.6, 422.6) |
15.5% |
0.14 |
0.126 |
|
Urine Naphthols2 (NAP) |
20046.3 (16281.8, 24681.3) |
22904.8 (19809.2, 26481.5) |
14.3% |
0.13 |
0.209 |
|
(ng/g creatinine) Urine |
|||||
|
Hydroxyfluorenes2 (FLUOR) |
2616.3 (2121.1, 3226.7) |
3196.1 (2651.3, 3852.6) |
22.2% |
0.20 |
0.013 |
|
(ng/g creatinine) Urine |
|||||
|
Hydroxyphenanthrenes2 (PHEN) |
469.1 (391.4, 562.3) |
546.6 (458.2, 652.0) |
16.5% |
0.15 |
0.061 |
|
(ng/g creatinine) Urine |
|||||
|
1-hydroxypyrene 2 (PYR) (ng/g creatinine) |
162.4 (124.0, 212.7) |
200.6 (155.6, 258.6) |
23.5% |
0.21 |
0.018 |
|
|
|||||
|
Notes: Means adjusted for age, gender, race/ethnicity, brand, total volume, IPI, velocity 1. Arithmetic mean 2. Geometric mean The table above shows the geometric average values, percent change Pre and Post RIP compliance, B and statistical significance for all biomarker variables. The model is adjusted for age, gender, race, brand, and topography covariates. All significant changes are noted by bold p values. All participants who did not complete the study were excluded for analysis. |
|||||
|
June et al. Tobacco Induced Diseases 2011 9:13 doi:10.1186/1617-9625-9-13 |
|||||
